Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EBITDA (2020 - 2025)

Historic EBITDA for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $620000.0.

  • Xeris Biopharma Holdings' EBITDA rose 10394.33% to $620000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7519.1%. This contributed to the annual value of -$54.8 million for FY2024, which is 1191.99% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EBITDA is $620000.0, which was up 10394.33% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' EBITDA ranged from a high of $620000.0 in Q3 2025 and a low of -$50.8 million during Q4 2021
  • Moreover, its 5-year median value for EBITDA was -$16.8 million (2023), whereas its average is -$18.2 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' EBITDA crashed by 13186.65% in 2021 and then surged by 10394.33% in 2025.
  • Xeris Biopharma Holdings' EBITDA (Quarter) stood at -$50.8 million in 2021, then surged by 74.57% to -$12.9 million in 2022, then dropped by 3.48% to -$13.4 million in 2023, then surged by 61.68% to -$5.1 million in 2024, then soared by 112.1% to $620000.0 in 2025.
  • Its EBITDA was $620000.0 in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.2 million in Q1 2025.